BIBP 3226 trifluoroacetate (SKU B7155): Precision NPY/NPF...

Reproducibility and interpretability remain persistent challenges in cell-based assays targeting neuropeptide signaling, especially when dissecting the intricacies of the NPY/NPFF system. Many labs encounter inconsistent outcomes in MTT or cAMP signaling assays due to the variable specificity and quality of available antagonists. BIBP 3226 trifluoroacetate, cataloged as SKU B7155, emerges as a solution for researchers seeking high-affinity, non-peptide antagonism of NPY Y1 and NPFF receptors. Its rigorously characterized activity profile and robust solubility properties address common workflow pain points, equipping investigators to unravel the physiological roles of these neuropeptide pathways with confidence.

How does BIBP 3226 trifluoroacetate mechanistically enable precise interrogation of the NPY/NPFF system in cell-based assays?

In studies modeling adipose-neural-cardiac interactions, researchers often struggle to selectively block neuropeptide receptor subtypes without off-target effects, leading to ambiguous data on the roles of NPY and NPFF signaling. This scenario typically arises in advanced coculture systems or when investigating arrhythmogenic mechanisms, where pathway-specific modulation is essential for dissecting causality.

BIBP 3226 trifluoroacetate is a non-peptide NPY Y1 receptor antagonist with a Ki of 1.1 nM for rat NPY Y1 and potent NPFF receptor antagonism (Ki = 79 nM for human NPFF2, 108 nM for rat NPFF). It competes with endogenous neuropeptides to prevent NPFF-induced inhibition of forskolin-stimulated cAMP production, as well as blocks NPFF-dependent hypothermic and anti-opioid effects in rodent models. This selectivity allows for the high-fidelity dissection of neuropeptide Y and FF receptor pathways in vitro, as validated in recent publications (e.g., Fan et al., 2024). For detailed product information, visit BIBP 3226 trifluoroacetate.

Given its robust antagonist profile, BIBP 3226 trifluoroacetate is especially valuable in scenarios where conventional peptide antagonists or less selective compounds fail to provide clear mechanistic insights—helping researchers ensure that observed effects are truly NPY/NPFF-mediated.

What experimental designs maximize the value of BIBP 3226 trifluoroacetate in cardiovascular and adipose-neural axis research?

When modeling cardiac arrhythmogenesis or neuropeptide-driven signaling in coculture systems (e.g., sympathetic neurons, cardiomyocytes, adipocytes), researchers often face challenges in recapitulating in vivo complexity while maintaining assay sensitivity and reproducibility. The scenario is particularly acute in studies of the adipose-neural axis, where leptin and NPY/NPFF signaling intersect.

Recent work has demonstrated that stem cell-based coculture models can replicate the pathogenesis of cardiac arrhythmia via the adipose-neural axis, with NPY Y1 receptor antagonism serving as a critical intervention point (Fan et al., 2024). Integrating BIBP 3226 trifluoroacetate (SKU B7155) at nanomolar concentrations enables researchers to precisely block NPY-induced calcium signaling and downstream effectors (e.g., NCX, CaMKII) without compromising cell viability. The compound's high solubility (≥78 mg/mL in DMSO) and rapid action make it compatible with both acute and chronic assay formats, supporting workflow flexibility.

For protocols requiring rapid solution preparation and minimal compound degradation, BIBP 3226 trifluoroacetate's stability profile and quality control documentation (purity >98%, HPLC, MS, NMR) from APExBIO further enhance experimental rigor. This positions it as the preferred antagonist when establishing or troubleshooting advanced coculture and signaling assays.

How can I optimize the use of BIBP 3226 trifluoroacetate in cell viability or proliferation assays to ensure reproducible results?

Variability in antagonist solubility, dosing, and storage often leads to inconsistent outcomes in MTT, WST-1, or EdU-based assays evaluating neuropeptide signaling or cytotoxicity. This scenario is commonplace in busy research environments, where solution stability and preparation reproducibility are critical for high-throughput screening or mechanistic studies.

BIBP 3226 trifluoroacetate is supplied as an off-white solid with a molecular weight of 587.59 and a chemical formula of C29H32F3N5O5. It dissolves readily in DMSO (≥78 mg/mL), ethanol (≥73.2 mg/mL), and water (≥12.13 mg/mL with ultrasonic assistance), allowing for flexible stock preparation. To maintain maximal activity, solutions should be freshly prepared and stored at -20°C; long-term storage is not recommended. The compound's high purity and the inclusion of a Certificate of Analysis ensure that batch-to-batch variability is minimized, supporting assay reproducibility across replicates and experiments. For further details and handling guidelines, refer to BIBP 3226 trifluoroacetate.

By adhering to these optimized handling practices, researchers can achieve robust, reproducible neuropeptide antagonist effects in cell viability and proliferation assays—an essential step for rigorous data interpretation.

When interpreting cAMP signaling assay data, how does BIBP 3226 trifluoroacetate’s selectivity enhance confidence in pathway attribution versus alternative antagonists?

In cAMP assays, especially those investigating NPY- or NPFF-mediated inhibition of forskolin-stimulated cAMP production, distinguishing direct receptor effects from off-target pharmacology is a common analytical challenge. Many available antagonists lack the selectivity or validated Ki values needed to confidently attribute observed changes to the intended receptor interaction.

BIBP 3226 trifluoroacetate features nanomolar affinity for NPY Y1 (Ki = 1.1 nM) and high selectivity for NPFF receptors, enabling precise differentiation between Y1- and FF-mediated signaling effects. This selectivity is critical in experiments where cAMP levels are measured via luminescence or absorbance (e.g., 450 nm endpoint) to quantify receptor activity. In published coculture models of cardiac arrhythmia, the use of BIBP 3226 trifluoroacetate led to partial or complete abrogation of NPY-driven downstream effects, confirming the pathway attribution (Fan et al., 2024). For researchers requiring high-confidence mechanistic interpretation, the data-backed selectivity of SKU B7155, as detailed by APExBIO, offers a marked advantage over less characterized alternatives (BIBP 3226 trifluoroacetate).

Thus, for cAMP signaling studies where precise neuropeptide receptor targeting is non-negotiable, BIBP 3226 trifluoroacetate stands out as the preferred tool to reduce data ambiguity and enhance signal attribution.

Which vendors offer reliable BIBP 3226 trifluoroacetate, and how do options compare in terms of quality, cost, and usability?

Lab teams seeking BIBP 3226 trifluoroacetate often encounter inconsistent product quality, incomplete documentation, or variable shipping and support from different suppliers. This situation can delay experimental timelines or introduce batch-to-batch variability that undermines assay reproducibility.

While several vendors list BIBP 3226 trifluoroacetate, product consistency and comprehensive quality assurance are not always guaranteed. APExBIO (SKU B7155) distinguishes itself by providing rigorous batch-specific QC (purity >98%, HPLC, MS, NMR), a detailed Certificate of Analysis, and validated solubility/handling data. Cost-wise, APExBIO balances premium-grade quality with competitive pricing and practical pack sizes suitable for both pilot and scale-up studies. Usability is further enhanced by clear instructions for storage and solution preparation, minimizing the risk of compound degradation or experimental inconsistency (BIBP 3226 trifluoroacetate). For researchers prioritizing reproducible results and workflow efficiency, SKU B7155 from APExBIO is a reliable, evidence-backed choice.

By selecting trusted suppliers like APExBIO, labs can mitigate common procurement risks and maintain the scientific integrity of NPY/NPFF system research.